Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “outperform” rating reiterated by equities researchers at Leerink Swann in a research report issued on Monday, AmericanBankingNews.com reports.
AMRN has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “positive” rating on shares of Amarin Co. plc in a research note to investors on Thursday. Separately, analysts at Goldman Sachs Group Inc. raised their price target on shares of Amarin Co. plc from $3.00 to $9.00 in a research note to investors on Wednesday, October 9th. They now have a “neutral” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Amarin Co. plc in a research note to investors on Tuesday, September 17th. They set a “neutral” rating on the stock. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Amarin Co. plc has a consensus rating of “Buy” and a consensus target price of $12.14.
Shares of Amarin Co. plc (NASDAQ:AMRN) opened at 5.09 on Monday. Amarin Co. plc has a 52 week low of $5.01 and a 52 week high of $12.96. The stock has a 50-day moving average of $6.57 and a 200-day moving average of $6.46. The company’s market cap is $878.6 million.
Amarin Co. plc (NASDAQ:AMRN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. Analysts expect that Amarin Co. plc will post $-1.37 EPS for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.